基因诊断在苯妥英治疗癫痫病中的应用

摘要/Abstract

摘要： 以近期发表的文献为依据,从分析苯妥英的体内代谢过程和基因诊断的基本理论,以及介绍成功应用基因诊断于苯妥英临床合理应用的实例入手,对利用基因诊断提高苯妥英合理应用水平的理论依据、临床意义、具体方法及适用范围等进行全面的阐述。基因多态是影响苯妥英药效学、药动学和药物不良反应的重要因素。基因诊断可成为提高苯妥英合理应用的有效方法,在苯妥英钠治疗癫痫病中应得到广泛的应用。

关键词: 苯妥英, 基因多态, 基因诊断

Abstract: To analyze in vivo the metabolic process of phenytoin and the basic theories of gene diagnosis, and introduce the examples of successful application of gene diagnosis in clinical phenytoin usage , and thoroughly expound the theoretical basis , clinical relevance, specific methods , and fields of application of using gene diagnosis to improve the usage of phenytoin ,using recently published literature as a basis.The genetic polymorphism is an important factor that affects the pharmacodynamics , pharmacokinetics , and drug adverse reaction of phenytoin.Gene diagnosis may become an effective way of improving usage of phenytoin and should be used widely in treating epilepsy with phenytoin.

Key words: phenytoin, genetic polymorphism, gene diagnosis

中图分类号:

R971+.6

刘扬, 宋亚娟, 丁国华. 基因诊断在苯妥英治疗癫痫病中的应用[J]. 中国临床药理学与治疗学, 2009, 14(4): 465-470.

LIU Yang, SONG Ya-juan, DING Guo-hua. Application of gene diagnosis in treatment of phenytoin for epilepsy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 465-470.

参考文献

[1] 张世玲.抗癫痫药与抗惊厥药[M] 李瑞, 主编.药理学.6 版.北京:人民卫生出版社, 2007:130.
[2] Magnus IS.Implication of polymorphic cytochrome P450-dependent drug metabolism for drug development[J].Drug Metab Dispos, 2001, 29(4):570-573.
[3] Komatsu T, Yamazaki H, Asahi S, et al.Formation of a dihydroxy netabolite of phenytoin in human liver microsomes cytosol:roles of cytochromes P450 2C9, 2C19 and 3A4[J].Drug Metab Dispos, 2000, 28(11):1361-1368.
[4] Lee CR, Goldstein J, Pieper JA.Cytochrom P450 2C9 polymorphisrrs:a comprehensive review of the in vitro and human data[J].Pharmacogenefcs, 2002, 12(3):251-263.
[5] Allabi AC, Gaia JL, Horsmans Y, et al.Functional impact of CYP2C9 ＊5, CYP2C9＊6, CYP2C9 ＊8 and CYP2C9 ＊11 in viv among black Africans[J].Clin Pharmacol Ther, 2004, 76(2):113-118.
[6] Blaisdell J, Jorge-Nebert LF, Coulter S, et al.Discovery of new potentially defective alleles of human CYP2C9[J]. Pharmacogenetics, 2004, 14(8):527-537.
[7] Si D, Guo Y, Zhang Y, et al.Identification of a novelvariant CYP2C9 allele in Chinese[J].Pharmacogenetics, 2004, 14(7):465-469.
[8] Zhao F, Loke C, Rankin SC, et al.Novel CYP2C9 genetic variants in Asian subjects and their in fluence on maintenance warfarin dose[J].Clin Pharmacol Ther, 2004, 76(3):210-219.
[9] Veenstra DL, Blough DK, Higashi MK, et al.CYP2C9 haplotype structure in European American warfarin patientsand association with clinical outcomes[J].Clin Pharmacol Ther, 2005, 77(5):353-364.
[10] Herman D, Peternel P, Stegnar M, et al.A novel sequence variant in exon7 of CYP2C9 gene (CYP2C9＊24)in a patient on war farin therapy[J].Thromb Haemost,2006, 95(1):192-194.
[11] Maekawa K, Fukushima H, Tohkin M, et al.Four novel defective alleles and comprehensive haplotypeanalysis of CYP2C9 in Japanese [J]. Pharmacogene Genomics, 2006, 16(7):497-514.
[12] Blaisdell J, Mohrenweiser H, Jackson J, et al.Identification and functional characterization of new potentially defective alleles of human CYP2C19[J].Pharmacogenetics, 2002, 12(9):701-711.
[13] Lee SY, Lee ST, Kim JW.Contributi ons of CYP2C9 CYP2C19 genoty pes and drug interacti on to the phenytoin treat ment in the Korean epileptic patients in the clinical setting[J].Biochem MolBiol, 2007, 409(2):448-452.
[14] 齐晓涟, 黄越, 王育琴, 等.苯妥英钠血药浓度与CYP2C19 基因多态性关系的研究[J].中国新药杂志, 2004, 13(10):922-925.
[15] 黄越, 杨静芳, 齐晓涟, 等.CYP2C19 和CYP2C9 基因型与苯妥英血药浓度关系的研究[J].中华医学杂志, 2004, 84(20):1686-1689.
[16] Vander J, Teijns LS, VanMJ, et al.The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement[J].Pharmacogenetics, 2001, 11(4):287-291.
[17] Kidd RS, Curry TB, Gallagher S, et al.Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin[J].Pharmacogenetics, 2001, 11(9):803-808.
[18] 任浩洋, 常红霞, 文思远.CYP2C9 基因多态性对苯妥英体内代谢的影响[J].科学技术与工程杂志,2008, 8(8):1976-1979.
[19] Yukawa E, Mamiya K.Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using non-linear mixed effects model approach[J].Clin Pharm Ther, 2006, 31(3):275-282.
[20] Klotz U.The role of pharmacogenetics in the metabolism of antiepileptic drugs:pharmacokinetic and therapeutic implications[J].Clin Pharmacokinet, 2007, 46(4):271-279.
[21] Rosemary J, Surendiran A, Rajan S, et al.Influence of the CYP2C9 and CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India[J].Indian J Med Res, 2006, 12(3):665-670.
[22] Hung CC, Lin CJ, Chen CC, et al.Dosage recommendation of phenytoin for patient with epilepsy eith different CYP2C9 CYP2C19 polymorphisms[J].Ther Drug Monit, 2004, 26(5):534-540.
[23] 张青霞, 姜德春, 王育琴.中国人群难治性癫痫患者CYP2C19＊2 基因型对癫痫耐药的影响[J].中国药物依赖性杂志, 2008, 17(2):115-119.
[24] Vander J, Steijns LS, Van MJ, et al.Maintenance dose requirement for phenytoin is lowered in genetically impaired drug metabolism independent of concommitant useof other antiepileptics[J].Ned-Tijdschr-Geneeskd, 2001, 145(7):312-315.
[25] Hung CC, Lin CJ, Chen CC, et al.Dosage recommendation of phenytoin for patient with epilepsy with different CYP2C9 CYP2C19 polymorphisms[J].Ther Drug Monit, 2004, 26(5):534-540.
[26] Saito K, Shimizu K, OkazakiM, et al.Application of the polymorphism of the CYP genes to the therapeutic anagement and counseling of patients[J].Jpn J Pharm Health Care Sci, 2001, 27(3):228.
[27] 丁国华, 冯彬, 高宏.基因诊断在临床药学中的应用 [J].中国医院药学杂志, 2003, 23(3):166-167.
[28] 王丽, 徐晓薇.药物相关基因检测对临床合理用药的指导意义[J].中国医院药学杂志, 2008, 28(21): 1865-1868.
[29] 武雪梅, 肖华胜.人类基因组结构变异检测研究进展[J].中国科学杂志, 2009, 39(3):237-244.
[30] 陈昆, 王睿, 文思远, 等.用基因芯片技术测定健康人群P450 2C9 基因多态性[J].中国临床药理学杂志,2005, 21(3):176-179.
[31] 李健, 丛玉隆, 文思远, 等.CYP450 热点突变基因芯片分型方法的建立[J].军医进修学院学报, 2007, 28(3):179-180.
[32] Toriello M, Meccariello P, Mazzaccara C, et al.Comparison of the taqMan and light cycler systems in pharmacogenetic testing:evaluation of CYP2C9 ＊2 ＊3 polymorphisms [J].Clin Chem Lab Med, 2006, 44(3):285-287.
[33] Tanigawara Y, Kita T, Hirono M, et al.Identification of nacetyltransferase and CYP2C19 genotypes for hair, buccal cell swabs, or fingernails compared with blood[J].Ther Drug Monit, 2001, 23(4):341-346.
[34] Anderson GD.Pharmacokinetic, pharmacodynamic and pharmacogenetic targeted therapy of antiepileptic drugs[J].Ther Drug Monit, 2008, 30(2):173-180.